For primary AML leukaemia blast with FLT3/ITD mutation, CD44v6 CAR‐T presented significant anti‐leukaemia effects but no obvious killing to the healthy donor, indicating the safety of normal myeloid cells. The gene discussed is FLT3; the disease is leukemia.